Shaping the renaissance of psychedelic research

The Lancet

Volumn 380, Issue 9838, 2012, Pages 200-201

  Sessa, Ben ^a  

^a Foundation House   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; IBOGAINE; KETAMINE; LYSERGIDE; PSILOCYBINE; PSYCHEDELIC AGENT;

ALCOHOLISM; ANXIETY DISORDER; CANCER PAIN; CLUSTER HEADACHE; DEPRESSION; DRUG DEPENDENCE; DRUG SAFETY; FUNCTIONAL NEUROIMAGING; HUMAN; METHAMPHETAMINE DEPENDENCE; NATIONAL HEALTH SERVICE; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSESSIVE COMPULSIVE DISORDER; OPIATE ADDICTION; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PSYCHOTHERAPY; TOBACCO DEPENDENCE; TREATMENT DURATION; ARTICLE; MENTAL DISEASE; METHODOLOGY; RESEARCH;

HALLUCINOGENS; HUMANS; MENTAL DISORDERS; PSYCHOTHERAPY; RESEARCH;

EID: 84864054843     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)60600-X     Document Type: Note

References (13)

1. Malleson N. Acute adverse reactions to LSD in clinical and experimental use in the United Kingdom. Br J Psychiatry 1971; 118: 229-30.
2. Sessa B. Can psychedelics have a role in psychiatry again? Br J Psychiatry 2005; 186: 457-58. (Pubitemid 40834862)
3. Nutt DJ, King LA, Saulsbury W, Blakemore C. Development of a rational scale to assess the harm of drugs of potential misuse. Lancet 2007; 369: 1047-53. (Pubitemid 46436128)
4. Grob CS, Danforth AL, Chopra GS, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry 2011; 68: 71-78.
5. Moreno FA, Wiegand CB, Taitano EK, Delgado PL. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry 2006; 67: 1735-40. (Pubitemid 44955154)
6. Krupitsky EM, Burakov AM, Dunaevsky IV, Romanova TN, Slavina TY, Grinenko AY. Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence. J Psychoactive Drugs 2007; 39: 13-19. (Pubitemid 46764228)
7. Zarate CA, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006; 63: 856-64. (Pubitemid 44188478)
8. Griffiths RR, Richards WA, McCann U, Jesse R. Psilocybin can occasion mystical experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl) 2006; 187: 268-83. (Pubitemid 44088380)
9. Carhart-Harris R, Leech R, Williams TM, et al. Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin. Br J Psychiatry 2012; 200: 238-44.
10. Sewell RA, Halpern JH, Pope HG Jr. Response of cluster headache to psilocybin and LSD. Neurology 2006; 66: 1920-22. (Pubitemid 44049828)
11. Sessa B. Could MDMA be useful in the treatment of post-traumatic stress disorder? Prog Neurol Psychiatry 2011; 6: 4-7.
12. Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Doblin R. The safety and efficacy of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol 2010; 25: 439-52.
13. Wade D, Harrigan S, Edwards J, Burgess PM, Whelan G, McGorry PD. Substance misuse in first-episode psychosis: 15-month prospective follow-up study. Br J Psychiatry 2006; 189: 229-34. (Pubitemid 44343467)